• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Seasonal Inflenza - Pipeline Review, H2 2012 Product Image

Seasonal Inflenza - Pipeline Review, H2 2012

  • ID: 2298656
  • October 2012
  • 93 pages
  • Global Markets Direct

Seasonal Inflenza – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Seasonal Inflenza - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Seasonal Inflenza, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Seasonal Inflenza. Seasonal Inflenza - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Seasonal Inflenza.
- A review of the Seasonal Inflenza products under development by companies and universities/research institutes READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Seasonal Inflenza Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Seasonal Inflenza 10
Seasonal Inflenza Therapeutics under Development by Companies 12
Seasonal Inflenza Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Seasonal Inflenza Therapeutics – Products under Development by Companies 20
Seasonal Inflenza Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Seasonal Inflenza Therapeutics Development 22
GlaxoSmithKline plc 22
Merck & Co., Inc. 23
ACE BioSciences A/S 24
Forest Laboratories, Inc. 25
Intercell AG 26
SIGA Technologies, Inc. 27
Panacea Biotec Limited 28
Eurocine Vaccines AB 29
Mucosis B.V. 30
GlycoVaxyn AG 31
Aquapharm Biodiscovery Limited 32
aRigen Pharmaceuticals, Inc. 33
Sinovac Biotech Ltd. 34
Genocea Biosciences, Inc. 35
NasVax Ltd. 36
Morphochem AG 37
Seasonal Inflenza – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
Pneumococcal Conjugate Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Sortase Inhibitor - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Pneumococcus Antibodies - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ACE-720 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
V-114 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Pneumococcal Vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
PneuGEM Vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CPG 7909 + Pneumococcal Vaccines - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Synflorix + Hiberix - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Heptavalent Pneumococcal Conjugate Vaccine + Polyvalent Pneumococcal Vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
GSK-2189242-A - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Streptococcus Pneumoniae Vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Nasal Pneumococcal Vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ceftaroline fosamil + avibactam sodium - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Prevenar - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Prevenar - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
S. Pneumoniae Paediatric Next Generation Vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Inactivated Influenza Vaccine + 23-Valent Pneumococcal Vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Synflorix + Infanrix Hexa - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Pneumococcus - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Pneumococcal Vaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
GSK2189242A + GSK1024850A - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
V-419 + Prevnar 13 + RotaTeq - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 74
Pneumococcal Polysaccharides Vaccine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
PlyD-1 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
AQP-182 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
MCB-3837 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Seasonal Inflenza Therapeutics – Drug Profile Updates 80
Seasonal Inflenza Therapeutics – Discontinued Products 83
Seasonal Inflenza Therapeutics - Dormant Products 84
Seasonal Inflenza – Product Development Milestones 85
Featured News & Press Releases 85
Sep 17, 2012: GSK Announces Submission For New Indication For Synflorix In Europe 85
Sep 07, 2012: Kalidex Pharma To Present Clinical Data On Next-generation Fluoroquinolone KPI-10 At ICAAC 2012 85
Sep 05, 2012: Rib-X Pharma To Present Data On RX-04 Program At ICAAC 2012 86
Aug 06, 2012: Aquapharm Biodiscovery Discovers New Antibiotic Compound 87
Mar 27, 2012: Lorus Therapeutics Announces Positive Results From Small Molecule Antimicrobial Program 87
Apr 26, 2011: National Advisory Committee On Immunization Recommends On Use Of Prevnar 13 88
Mar 03, 2011: Sinovac Biotech Submits Clinical Trial Application To SFDA For Pneumococcal Conjugate Vaccine 88
Oct 29, 2010: Forest Receives FDA Approval For Teflaro For Treatment Of Community-Acquired Bacterial Pneumonia And Acute Bacterial Skin And Skin Structure Infection 89
Oct 15, 2010: Cempra To Present New Data On Solithromycin At Annual Meeting Of Infectious Diseases Society Of America 90
Sep 09, 2010: Cempra Presents New Data On Solithromycin At 50th Interscience Conference On Antimicrobial Agents And Chemotherapy 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 93
Disclaimer 93

List of Tables
Number of Products Under Development for Seasonal Inflenza, H2 2012 10
Products under Development for Seasonal Inflenza – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Development by Companies, H2 2012 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Comparative Analysis by Late Stage Development, H2 2012 16
Comparative Analysis by Mid Clinical Stage Development, H2 2012 17
Comparative Analysis by Early Clinical Stage Development, H2 2012 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 21
GlaxoSmithKline plc, H2 2012 22
Merck & Co., Inc., H2 2012 23
ACE BioSciences A/S, H2 2012 24
Forest Laboratories, Inc., H2 2012 25
Intercell AG, H2 2012 26
SIGA Technologies, Inc., H2 2012 27
Panacea Biotec Limited, H2 2012 28
Eurocine Vaccines AB, H2 2012 29
Mucosis B.V., H2 2012 30
GlycoVaxyn AG, H2 2012 31
Aquapharm Biodiscovery Limited, H2 2012 32
aRigen Pharmaceuticals, Inc., H2 2012 33
Sinovac Biotech Ltd., H2 2012 34
Genocea Biosciences, Inc., H2 2012 35
NasVax Ltd., H2 2012 36
Morphochem AG, H2 2012 37
Assessment by Monotherapy Products, H2 2012 38
Assessment by Combination Products, H2 2012 39
Assessment by Stage and Route of Administration, H2 2012 41
Assessment by Stage and Molecule Type, H2 2012 43
Seasonal Inflenza Therapeutics – Drug Profile Updates 80
Seasonal Inflenza Therapeutics – Discontinued Products 83
Seasonal Inflenza Therapeutics – Dormant Products 84

List of Figures
Number of Products under Development for Seasonal Inflenza, H2 2012 10
Products under Development for Seasonal Inflenza – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 15
Late Stage Products, H2 2012 16
Mid Clinical Stage Products, H2 2012 17
Early Clinical Stage Products, H2 2012 18
Discovery and Pre-Clinical Stage Products, H2 2012 19
Assessment by Monotherapy Products, H2 2012 38
Assessment by Combination Products, H2 2012 39
Assessment by Route of Administration, H2 2012 40
Assessment by Stage and Route of Administration, H2 2012 41
Assessment by Molecule Type, H2 2012 42
Assessment by Stage and Molecule Type, H2 2012 43

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos